Try
Thermo Fisher Scientific Inc.
TMOUnited States
54 filed reports · 617 financial concepts · 41 earnings calls · 5 media appearances
Filed reports
54 reports · Jul 2016 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 106 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 31 | 6,506 | Jul 2016 to Jun 2026 |
| Current · 8-KSEC EDGAR | 13 | 52 | Jun 2019 to Sep 2024 |
| Annual · 10-KSEC EDGAR | 10 | 6,740 | Dec 2016 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 27, 2026 | Jul 31, 2026 | 463 | Open |
| FY2026 Q1 | 10-Q | Mar 28, 2026 | May 1, 2026 | 365 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 26, 2026 | 1,285 | Open |
| FY2025 Q3 | 10-Q | Sep 27, 2025 | Oct 31, 2025 | 362 | Open |
| FY2025 Q2 | 10-Q | Jun 28, 2025 | Aug 1, 2025 | 243 | Open |
| FY2025 Q1 | 10-Q | Mar 29, 2025 | May 2, 2025 | 238 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 20, 2025 | 606 | Open |
| FY2024 Q3 | 10-Q | Sep 28, 2024 | Nov 1, 2024 | 194 | Open |
| FY2024 Q3 | 8-K | Sep 28, 2024 | Oct 23, 2024 | 4 | Open |
| FY2024 Q2 | 10-Q | Jun 29, 2024 | Aug 2, 2024 | 186 | Open |
| FY2024 Q2 | 8-K | Jun 29, 2024 | Jul 24, 2024 | 4 | Open |
| FY2024 Q1 | 10-Q | Mar 30, 2024 | May 3, 2024 | 177 | Open |
Financial data
617 concepts · 13,298 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial581 concepts · 11,693 facts · Dec 2014 to Jun 2026
- Dividends payable current and noncurrent58 · Dec 2014 to Jun 2026
- Revenue58 · Dec 2014 to Jun 2026
- Stockholders equity (US GAAP)58 · Dec 2014 to Jun 2026
- Cash and cash equivalents at carrying value57 · Dec 2014 to Jun 2026
- Comprehensive income net of tax57 · Dec 2014 to Jun 2026
- Costs and expenses57 · Dec 2014 to Jun 2026
- Depreciation57 · Dec 2014 to Jun 2026
- Income tax expense benefit57 · Dec 2014 to Jun 2026
- Incremental common shares attributable to share based payment arrangements57 · Dec 2014 to Jun 2026
- Investment income interest57 · Dec 2014 to Jun 2026
- Operating income loss57 · Dec 2014 to Jun 2026
- Other comprehensive income loss pension and other postretirement benefit plans adjustment before reclassification adjustments net of tax57 · Dec 2014 to Jun 2026
- Other comprehensive income loss pension and other postretirement benefit plans before reclassification adjustments tax57 · Dec 2014 to Jun 2026
- Other comprehensive income loss reclassification adjustment from AOCI pension and other postretirement benefit plans net of tax57 · Dec 2014 to Jun 2026
- Other comprehensive income loss reclassification adjustment from AOCI pension and other postretirement benefit plans tax57 · Dec 2014 to Jun 2026
- Other nonoperating income expense57 · Dec 2014 to Jun 2026
- Research and development expense57 · Dec 2014 to Jun 2026
- Restructuring and other costs, net57 · Dec 2014 to Jun 2026
- Selling general and administrative expense57 · Dec 2014 to Jun 2026
- Share based compensation57 · Dec 2014 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value56 · Dec 2014 to Jun 2026
- Dividends common stock cash56 · Dec 2014 to Jun 2026
- Income tax reconciliation income tax expense benefit at federal statutory income tax rate56 · Dec 2014 to Jun 2026
- Net cash provided by used in operating activities56 · Dec 2014 to Jun 2026
Segment27 concepts · 948 facts · Dec 2014 to Jun 2026
- Operating Income176 · Jun 2015 to Jun 2026
- Revenue156 · Jun 2015 to Jun 2026
- Revenue (excluding assessed tax)143 · Jul 2017 to Jun 2026
- Total Assets83 · Dec 2015 to Jun 2026
- Goodwill45 · Dec 2015 to Dec 2025
- Cost of Revenue39 · Dec 2023 to Jun 2026
- SG&A Expense38 · Dec 2023 to Jun 2026
- R&D Expense37 · Dec 2023 to Jun 2026
- Restructuring and other costs, net35 · Dec 2014 to Jun 2026
- Capital Expenditures29 · Dec 2015 to Dec 2022
- Total Restructuring and Other Costs (Income), Net28 · Dec 2014 to Oct 2021
- Segment Reconciling Items21 · Dec 2014 to Oct 2021
- Cost of revenue (US GAAP)13 · Dec 2023 to Jun 2026
- Depreciation13 · Dec 2023 to Jun 2026
- Operating income loss13 · Dec 2023 to Jun 2026
- Research and development expense13 · Dec 2023 to Jun 2026
- Segment expenditure addition to long lived assets13 · Dec 2023 to Jun 2026
- Segment reporting other item amount13 · Dec 2023 to Jun 2026
- Selling general and administrative expense13 · Dec 2023 to Jun 2026
- Payments to acquire property plant and equipment9 · Dec 2014 to Dec 2022
- Restructuring settlement and impairment provisions6 · Dec 2016 to Mar 2019
- Defined benefit plan recognized net gain loss due to settlements and curtailments13 · Dec 2014 to Oct 2016
- Restructuring charges3 · Oct 2016 to Dec 2016
- Goodwill acquired during period2 · Dec 2024 to Dec 2025
Geography2 concepts · 325 facts · Dec 2014 to Jun 2026
- Revenue313 · Dec 2014 to Jun 2026
- Property, Plant & Equipment, Net12 · Dec 2015 to Dec 2018
Product2 concepts · 276 facts · Dec 2016 to Jun 2026
- Revenue182 · Dec 2016 to Jun 2026
- Cost of goods and services sold (US GAAP)94 · Dec 2016 to Jun 2026
Guidance5 concepts · 56 facts · Jul 2019 to Jul 2026
- EPS (Diluted) Guidance22 · Jul 2019 to Oct 2024
- Revenue Guidance22 · Jul 2019 to Oct 2024
- Revenue Growth Guidance8 · Apr 2020 to Oct 2023
- Capital Expenditures Guidance2 · Jul 2026
- Effective Tax Rate Guidance2 · Jul 2026
Segments
1,549 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments25 members · 896 facts
- Analytical instruments158 · Jun 2015 to Mar 2026
- Life sciences solutions158 · Jun 2015 to Mar 2026
- Specialty diagnostics155 · Jun 2015 to Mar 2026
- Laboratory Products And Biopharma Services129 · Dec 2023 to Jun 2026
- Laboratory productsand services124 · Jun 2015 to Mar 2025
- Corporate90 · Dec 2014 to Dec 2022
- Laboratory products and biopharma services segment31 · Jun 2024 to Jun 2026
- Corporate And Other9 · Dec 2014 to Dec 2022
- Corporate and other8 · Dec 2015 to Dec 2022
- Laboratory products and biopharma services4 · Dec 2024 to Dec 2025
- Bio Production2 · Mar 2024 to Mar 2025
- Biosciences2 · Mar 2024 to Mar 2025
- Chemical Analysis2 · Mar 2024 to Mar 2025
- Chromatography And Mass Spectrometry2 · Mar 2024 to Mar 2025
- Clinical Diagnostics2 · Mar 2024 to Mar 2025
- Clinical Research2 · Mar 2024 to Mar 2025
- Electron Microscopy2 · Mar 2024 to Mar 2025
- Genetic Sciences2 · Mar 2024 to Mar 2025
- Healthcare Market Channel2 · Mar 2024 to Mar 2025
- Immunodiagnostics2 · Mar 2024 to Mar 2025
- Laboratory Products2 · Mar 2024 to Mar 2025
- Microbiology2 · Mar 2024 to Mar 2025
- Pharma Services2 · Mar 2024 to Mar 2025
- Research And Safety Market Channel2 · Mar 2024 to Mar 2025
- Transplant Diagnostics2 · Mar 2024 to Mar 2025
Statement geographicalsrt:StatementGeographicalAxis7 members · 282 facts
- Asia Pacific42 · Mar 2018 to Jun 2026
- Europe42 · Mar 2018 to Jun 2026
- North America42 · Mar 2018 to Jun 2026
- Other Regions42 · Mar 2018 to Jun 2026
- All Other Countries41 · Dec 2016 to Dec 2025
- US41 · Dec 2016 to Dec 2025
- CN32 · Dec 2016 to Jul 2023
Product or servicesrt:ProductOrServiceAxis6 members · 274 facts
- Product94 · Dec 2016 to Jun 2026
- Service94 · Dec 2016 to Jun 2026
- Consumables41 · Mar 2018 to Mar 2026
- Instruments41 · Mar 2018 to Mar 2026
- Product Consumables2 · Jun 2025 to Jun 2026
- Product Instruments2 · Jun 2025 to Jun 2026
Subsegments4 members · 52 facts
- Clinical Research13 · Dec 2023 to Jun 2026
- Laboratory Products13 · Dec 2023 to Jun 2026
- Pharma Services13 · Dec 2023 to Jun 2026
- Research And Safety Market Channel13 · Dec 2023 to Jun 2026
Statement geographicalus-gaap:StatementGeographicalAxis14 members · 43 facts
- All Other Countries6 · Dec 2014 to Mar 2018
- CN6 · Dec 2014 to Mar 2018
- US6 · Dec 2014 to Mar 2018
- Us4 · Dec 2015 to Dec 2018
- Gb3 · Dec 2015 to Dec 2017
- DE3 · Dec 2014 to Dec 2016
- GB3 · Dec 2014 to Dec 2016
- JP3 · Dec 2014 to Dec 2016
- All other countries3 · Dec 2015 to Dec 2018
- De2 · Dec 2015 to Dec 2016
- Asia Pacific1 · Mar 2018
- Europe1 · Mar 2018
- North America1 · Mar 2018
- Other Regions1 · Mar 2018
Product or serviceus-gaap:ProductOrServiceAxis2 members · 2 facts
- Consumables1 · Mar 2018
- Instruments1 · Mar 2018
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary86 claims from 8 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary193 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes5 claims from 1 reports · Dec 2025
- Risk factors56 risks from 2 annual reports · 2024 to 2025
Earnings calls
41 calls · Apr 2016 to Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 23, 2026
- FY2026 Q1Apr 23, 2026
- FY2025 Q4Jan 29, 2026
- FY2025 Q3Oct 22, 2025
- FY2025 Q2Jul 23, 2025
- FY2025 Q1Apr 23, 2025
- FY2024 Q4Jan 30, 2025
- FY2024 Q3Oct 23, 2024
- FY2024 Q2Jul 24, 2024
- FY2024 Q1Apr 24, 2024
- FY2023 Q4Jan 31, 2024
- FY2023 Q3Oct 25, 2023
- FY2023 Q2Jul 26, 2023
- FY2023 Q1Apr 26, 2023
- FY2022 Q4Feb 1, 2023
- FY2022 Q3Oct 26, 2022
Executive media
5 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- Other appearances2 · Jul 2020 to Feb 2023
- TV interviews2 · Mar 2020 to Sep 2021
- Conference talks1 · Sep 2022
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.